Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 yo With Birch Pollen-induced Allergic Rhinoconjunctivitis w/o Asthma

NCT05668390 is registered in ClinicalTrials.gov with Stallergenes Greer as lead sponsor.

NCT NCT05668390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 yo With Birch Pollen-induced Allergic Rhinoconjunctivitis w/o Asthma
Lead sponsor
Stallergenes Greer
Phase
Phase 3
Overall status
Completed
Start date
September 20, 2023
Completion date
August 6, 2025
Enrollment
553 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinoconjunctivitis, birch pollen allergy